搜尋結果
2021年8月23日 · Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA in individuals 16 years of age and older, and the authorization was expanded to include those 12 through 15 ...
2021年10月21日 · The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries.
Comirnaty: Fragen und Antworten zum Corona-Impfstoff von Biontech/Pfizer. Zuletzt aktualisiert am 8. Juni 2023. Der Impfstoff Comirnaty der Firmen Biontech und Pfizer war der erste in der EU zugelassene Impfstoff. Es handelt sich um einen mRNA-Impfstoff, der in mehreren Dosen verabreicht wird.
2022年8月18日 · 为体现免疫战略咨询专家组最新建议，于2022年8月18日更新。. 世卫组织免疫战略咨询专家组已发布使用辉瑞-生物科技（BNT162b2）COVID-19疫苗的临时建议。. 本文对这些临时建议做了归纳。. 你可以在 此处 查阅完整指导文件。. 以下是你需要了解的内容。. 免疫战略 ...
Do not administer Pfizer BioNTech COVID-19 Vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer BioNTech COVID-19 Vaccine Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer BioNTech COVID ...
2022年8月23日 · today announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported interim vaccine efficacy data ...
The Pfizer-BioNTech COVID-19 Vaccine is administered as a series of two doses, three weeks apart, the same dosage and dosing regimen for 16 years of age and older.
